1Wagner U,Schlebusch H,Kohler S,et al. Immunological responses to the tumor associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.Hybridoma,1997,16(1):33-40
2Wagner U, Reinartz S, Kohler S, et al. Immunological consolidation of ovarian carcinoma recurrence with monoclonal anti-iditype antibody ACA125:immune reponses and survival in patients treatment.Clin Cancer Res,2001,7(5):1154-1162
4Ozols RF. Future directions in the treatment of ovarian cancer.Semin Oncol,2002,29(1 suppl 1):32-42
5Windbichler GH,Hausmaninger H,Stummvoll W,et al.Interferon-gamma in the first-line therapy of ovarian carcer: a randomized phase III trial.Br J Cancer,2000,82(6):1138-1144
6Canevari S,Stoter G,Arienti F,et al.Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.J Natl Cancer Inst,1995,87(19):1463-1469
8Qian HN,Feng J,Cui H,et al. Generation and characterization of monoclonal antibody coc166-9 to human epithelial ovarian adenocarcinoma [J]. Sino-Jap J Allergology Imuno,1988,4(4):417- 423.
9Brossart P,Wirths S,Stuhler G,et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells [J]. Blood,2000,96(9):3102- 3108.
10Lodge PA,Jones LA,Bader RA,et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcionma cells [J]. Cancer Res,2000,60(4):829- 833.
